1. Does Olanzapine Warrant Clinical Pharmacokinetic Monitoring in Schizophrenia?

   • Erin Schwenger
   • Jane Dumontet
   • Mary H. H. Ensom

   Review Article 13 September 2012 Pages: 415 - 428

   

2. Structural Models Describing Placebo Treatment Effects in Schizophrenia and Other Neuropsychiatric Disorders

   • Venkatesh Pilla Reddy
   • Magdalena Kozielska
   • Johannes H. Proost

   Review Article 13 September 2012 Pages: 429 - 450

   

3. Influence of Cytochrome P450 3A5 (CYP3A5) Genetic Polymorphism on the Pharmacokinetics of the Prolonged-Release, Once-Daily Formulation of Tacrolimus in Stable Renal Transplant Recipients

   • François Glowacki
   • Arnaud Lionet
   • Christelle Cauffiez

   Short Communication 13 September 2012 Pages: 451 - 459

   

4. Lidocaine (Lignocaine) Dosing Regimen Based upon a Population Pharmacokinetic Model for Preterm and Term Neonates with Seizures

   • Marcel P. H. van den Broek
   • Alwin D. R. Huitema
   • Catharine M. A. Rademaker

   Review ArticleOriginal Research Article 13 September 2012 Pages: 461 - 469

   

5. Asenapine Pharmacokinetics in Hepatic and Renal Impairment

   • Pierre Peeters
   • Howard Bockbrader
   • Rik de Greef

   Original Research Article 13 September 2012 Pages: 471 - 481